Showing 181-190 of 9096 results for "".
The Dermatology Market: A Tidal Wave of Private Equity Investment
https://practicaldermatology.com/topics/practice-management/the-dermatology-market-a-tidal-wave-of-private-equity-investment/20416/A beginner's guide to the complex world of mergers and acquisitions.In-house or Outsourced Billing: What to Know to Make a Choice or a Change
https://practicaldermatology.com/topics/general-topics/in-house-or-outsourced-billing-what-to-know-to-make-a-choice-or-a-change/21799/There are pros and cons to each method. Research and preparation are essential to decision-making.The Microbiome in Acne: Where are We Now?
https://practicaldermatology.com/topics/acne-rosacea/the-microbiome-in-acne-where-are-we-now/23731/As research reveals connections of the microbiome to skin disease, clinicians may discover new approaches to managing the disease.The Future of Treatment and Research for Giant Congenital Melanocytic Nevi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-future-of-treatment-and-research-for-giant-congenital-melanocytic-nevi/57252/Congenital melanocytic nevi (CMN) have long posed a clinical paradox: lesions that are often benign in behavior yet burdened by a measurable risk of melanoma and significant psychosocial impact. Present at birth or emerging in early infancy, CMN vary widely in size, distribution, and long-term impliTips for Management of Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/tips-for-management-of-cutaneous-squamous-cell-carcinoma/57254/Cutaneous squamous cell carcinoma (cSCC) is one of the most common malignancies encountered in dermatologic practice. Current treatment guidelines for cSCC provide recommendations based largely on tumor risk classification, while emphasizing the importance of clinical judgment and patient-specific fSaving Medical Dermatology: Biologics and the Future of Patient Care
https://practicaldermatology.com/topics/practice-management/saving-medical-dermatology-biologics-and-the-future-of-patient-care/21211/Although prescription rates lag, biologic agents may hold the key to sustaining the specialty.Update: Biomarkers for Guiding Treatment in Early Stage Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/update-biomarkers-for-guiding-treatment-in-early-stage-melanoma/23260/A look at current tools for risk stratification of melanoma, controversy surrounding SLNB for staging, and novel adjuvant immunotherapies for early stage disease.An Overview of Topical Therapies for Managing Pediatric AD
https://practicaldermatology.com/topics/atopic-dermatitis/an-overview-of-topical-ththerapies-for-managing-pediatric-ad/54375/Moisturization is foundational in AD management; no specific formulation has demonstrated superiority, and excessive bathing may worsen disease via increased transepidermal water loss. Topical corticosteroids and calcineurin inhibitors remain first-line due to strong efficacy data, cost-effectiveneManagement of Female Pattern Hair Loss
https://practicaldermatology.com/topics/hair-nails/management-of-female-pattern-hair-loss/22975/Creating and maintaining healthy, normal hair growth and scalp skin is a daily activity that requires a lifestyle change to maintain the benefits of a good hair care program.A Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts
https://practicaldermatology.com/topics/general-topics/a-highly-effective-topical-compounded-medication-for-the-treatment-of-cutaneous-warts/20583/A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions to treat in dermatology.